LUNG Pulmonx Corp
FY2025 10-K
Pulmonx Corp (LUNG) filed its fiscal year 2025 10-K annual report with the SEC on Mar 10, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Minimally invasive treatment for severe emphysema using Zephyr Valve, Chartis System and LungTraX Platform
- • New emphasis: Global clinical trial CONVERT II for FDA approval of AeriSeal System, a synthetic polymer foam device with Breakthrough Device designation
Management Discussion & Analysis
- • Revenue $90.5M in 2025, up 8.0% YoY from $83.8M in 2024; US sales $57.0M (+$0.6M), International $33.5M (+$6.2M)
- • Gross margin 74.2% in 2025 vs 74.0% in 2024; cost of goods sold $23.4M up 7.2% mainly from volume increase
Risk Factors
- • FDA 510(k) clearance required for future products, uncertainty in obtaining approvals threatens product commercialization
- • Revenue exposure in US, Europe, and Asia Pacific vulnerable to economic conditions and hospital contracting delays
Financial SummaryXBRL
Revenue
$90M
Net Income
-$54M
Gross Margin
74.2%
Operating Margin
-59.3%
Net Margin
-59.7%
ROE
-99.8%
Total Assets
$129M
EPS (Diluted)
$-1.33
Operating Cash Flow
-$32M
Source: XBRL data from Pulmonx Corp FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Pulmonx Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.